Niacinamide Concept

subject area of

• N,N-Bis(2-mercaptoethyl)methylamine:  A New Coligand for Tc-99m Labeling of Hydrazinonicotinamide Peptides  Journal Articles
• A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186  Journal Articles
• A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: A trial of the Chicago, PMH, and California Phase II Consortia  Journal Articles
• A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer  Journal Articles
• A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer  Journal Articles
• A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium  Journal Articles
• A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study  Journal Articles
• BAY 43-9006: Early Clinical Data in Patients with Advanced Solid Malignancies  Journal Articles
• Changes in Liver Volume Observed Following Sorafenib and Liver Radiation Therapy  Journal Articles
• Evidence and values: requirements for public reimbursement of drugs for rare diseases--a case study in oncology.  Journal Articles
• Hazard assessment using an in-silico toxicity assessment of the transformation products of boscalid, pyraclostrobin, fenbuconazole and glyphosate generated by exposure to an advanced oxidative process  Journal Articles
• Metastatic renal cell cancer treatments: An indirect comparison meta-analysis  Journal Articles
• Phase I Targeted Combination Trial of Sorafenib and Erlotinib in Patients with Advanced Solid Tumors  Journal Articles
• Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors  Journal Articles
• Phase II Trial of Sorafenib in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Nasopharyngeal Carcinoma  Conferences
• Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?  Journal Articles
• Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma  Journal Articles
• Safety and Efficacy of Sorafenib in Elderly Patients Treated in the North American Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program  Journal Articles
• Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America  Journal Articles
• Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors  Journal Articles
• Sorafenib and Radiation Therapy for the Treatment of Advanced Hepatocellular Carcinoma  Journal Articles
• Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer: A Study of the Princess Margaret Hospital Phase II Consortium  Journal Articles
• Tetraethylammonium and nicotine transport by the Malpighian tubules of insects  Journal Articles
• Therapeutic Potential of Spleen Tyrosine Kinase Inhibition for Treating High-Risk Precursor B Cell Acute Lymphoblastic Leukemia  Journal Articles
• Waste Nitrogen Metabolism and Excretion in Zebrafish Embryos: Effects of Light, Ammonia, and Nicotinamide  Journal Articles
• [A new anti-ischemic drug for the treatment of stable effort angina pectoris: nicorandil. Comparison with placebo and isosorbide-5-mononitrate].  Journal Articles